Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNASDAQ:COYANASDAQ:SANANASDAQ:TRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$5.81+8.3%$5.09$3.55▼$11.16$447.14M1.132.85 million shs2.60 million shsCOYACoya Therapeutics$6.21+4.0%$6.13$4.65▼$10.24$103.86M0.4973,072 shs35,962 shsSANASana Biotechnology$1.82+6.8%$1.95$1.26▼$9.49$409.24M1.753.32 million shs2.45 million shsTRMLTourmaline Bio$15.74+2.3%$15.43$11.56▼$29.79$404.28M2.11271,046 shs133,574 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+6.56%+2.10%+34.67%-22.43%-26.27%COYACoya Therapeutics+3.96%-8.27%+12.15%-13.64%-25.37%SANASana Biotechnology-0.58%-10.53%+11.11%-47.85%-83.07%TRMLTourmaline Bio+5.85%-10.58%+21.95%+2.67%-2.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.1237 of 5 stars3.51.00.00.01.53.30.6COYACoya Therapeutics1.8998 of 5 stars3.53.00.00.02.40.80.0SANASana Biotechnology1.86 of 5 stars3.40.00.00.01.73.30.6TRMLTourmaline Bio2.7712 of 5 stars3.53.00.00.03.82.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 3.00Buy$20.83258.82% UpsideCOYACoya Therapeutics 3.00Buy$17.00173.75% UpsideSANASana Biotechnology 2.86Moderate Buy$10.80495.04% UpsideTRMLTourmaline Bio 3.00Buy$49.33213.43% UpsideCurrent Analyst Ratings BreakdownLatest COYA, SANA, ALT, and TRML Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.005/5/2025TRMLTourmaline BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.004/28/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/24/2025SANASana BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.004/23/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.004/22/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/27/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/20/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/18/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/18/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K22,357.16N/AN/A$2.75 per share2.11COYACoya Therapeutics$3.55M29.22N/AN/A$2.47 per share2.51SANASana BiotechnologyN/AN/AN/AN/A$1.46 per shareN/ATRMLTourmaline BioN/AN/AN/AN/A$10.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.34N/AN/AN/A-199,076.92%-55.81%-50.60%5/8/2025 (Estimated)COYACoya Therapeutics-$7.99M-$0.98N/AN/AN/AN/A-31.63%-27.76%5/8/2025 (Estimated)SANASana Biotechnology-$283.26M-$1.16N/AN/AN/AN/A-84.22%-44.97%5/14/2025 (Estimated)TRMLTourmaline Bio-$42.12M-$3.21N/AN/AN/AN/A-20.97%-20.56%N/ALatest COYA, SANA, ALT, and TRML EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SANASana Biotechnology-$0.22-$0.20+$0.02-$0.21N/AN/A5/12/2025Q1 2025TRMLTourmaline Bio-$0.91N/AN/AN/AN/AN/A5/8/2025Q1 2025ALTAltimmune-$0.36N/AN/AN/A$0.00 millionN/A5/8/2025Q1 2025COYACoya Therapeutics-$0.44N/AN/AN/AN/AN/A5/2/2025Q1 2025TRMLTourmaline Bio-$0.91-$0.89+$0.02-$0.89N/AN/A3/18/2025Q4 2024COYACoya Therapeutics-$0.32-$0.18+$0.14-$0.18$0.10 million$0.20 million3/17/2025Q4 2024SANASana Biotechnology-$0.25-$0.23+$0.02-$0.21N/AN/A3/13/2025Q4 2024TRMLTourmaline Bio-$0.91-$0.86+$0.05-$0.86N/A$0.04 million2/27/2025Q4 2024ALTAltimmune-$0.34-$0.33+$0.01-$0.33$0.00 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.8716.87COYACoya TherapeuticsN/A15.3115.31SANASana BiotechnologyN/A4.474.47TRMLTourmaline BioN/A40.3340.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%COYACoya Therapeutics39.75%SANASana Biotechnology88.23%TRMLTourmaline Bio91.89%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%COYACoya Therapeutics12.00%SANASana Biotechnology31.10%TRMLTourmaline Bio11.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5077.01 million68.21 millionOptionableCOYACoya Therapeutics616.73 million14.70 millionNot OptionableSANASana Biotechnology380225.48 million153.83 millionOptionableTRMLTourmaline Bio4425.69 million22.82 millionOptionableCOYA, SANA, ALT, and TRML HeadlinesRecent News About These CompaniesHC Wainwright Weighs in on Tourmaline Bio Q2 EarningsMay 8 at 6:22 AM | marketbeat.comFY2025 EPS Estimates for Tourmaline Bio Increased by AnalystMay 8 at 2:30 AM | americanbankingnews.comBrokers Offer Predictions for Tourmaline Bio Q2 EarningsMay 8 at 1:50 AM | americanbankingnews.comAnalysts Set Tourmaline Bio, Inc. (NASDAQ:TRML) Price Target at $49.33May 8 at 1:05 AM | americanbankingnews.comTourmaline Bio (NASDAQ:TRML) Receives "Buy" Rating from HC WainwrightMay 7 at 8:15 AM | marketbeat.comTourmaline Bio's (TRML) "Buy" Rating Reiterated at Chardan CapitalMay 7 at 8:15 AM | marketbeat.comTourmaline Bio (TRML) Expected to Announce Earnings on MondayMay 7 at 7:56 AM | marketbeat.comBrokers Issue Forecasts for Tourmaline Bio Q2 EarningsMay 7 at 4:09 AM | americanbankingnews.comTourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Barclays PLCMay 7 at 3:31 AM | marketbeat.comChardan Capital Reiterates "Buy" Rating for Tourmaline Bio (NASDAQ:TRML)May 7 at 1:23 AM | americanbankingnews.comTourmaline Bio Reports Q1 2025 Financial ResultsMay 7 at 1:17 AM | tipranks.comSusquehanna Fundamental Investments LLC Invests $467,000 in Tourmaline Bio, Inc. (NASDAQ:TRML)May 6 at 4:21 AM | marketbeat.comTourmaline Bio (NASDAQ:TRML) Earns "Buy" Rating from HC WainwrightMay 6 at 2:33 AM | americanbankingnews.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from BrokeragesMay 6 at 2:21 AM | marketbeat.comTourmaline Bio (NASDAQ:TRML) Issues Earnings ResultsMay 4, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Acuta Capital Partners LLCMay 4, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Acquires 100,139 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)May 4, 2025 | marketbeat.comWhy Tourmaline Bio, Inc.’s (TRML) Stock Is Down 7.00%May 3, 2025 | aaii.comTourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 3, 2025 | finanznachrichten.deTourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 2, 2025 | globenewswire.comNantahala Capital Management LLC Lowers Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML)April 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Top 3 S&P 500 Winners in a Losing MarketBy Ryan Hasson | April 9, 2025View Top 3 S&P 500 Winners in a Losing MarketOccidental’s Hidden Gem: How OxyChem Could Boost ProfitsBy Jea Yu | April 29, 2025View Occidental’s Hidden Gem: How OxyChem Could Boost ProfitsWith a 60%+ Upside, There’s Plenty to Love About LovesacBy Jea Yu | April 20, 2025View With a 60%+ Upside, There’s Plenty to Love About Lovesac3 Stocks to Buy Now for Tariff ImmunityBy Gabriel Osorio-Mazilli | April 23, 2025View 3 Stocks to Buy Now for Tariff ImmunityCOYA, SANA, ALT, and TRML Company DescriptionsAltimmune NASDAQ:ALT$5.81 +0.45 (+8.32%) Closing price 03:59 PM EasternExtended Trading$5.80 0.00 (-0.02%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Coya Therapeutics NASDAQ:COYA$6.21 +0.24 (+4.02%) Closing price 04:00 PM EasternExtended Trading$6.27 +0.06 (+0.90%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Sana Biotechnology NASDAQ:SANA$1.82 +0.12 (+6.76%) Closing price 03:59 PM EasternExtended Trading$1.80 -0.01 (-0.55%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Tourmaline Bio NASDAQ:TRML$15.74 +0.35 (+2.27%) Closing price 04:00 PM EasternExtended Trading$15.74 0.00 (0.00%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
